U.S. Medical Equipment Stock News

NYSE:DX
NYSE:DXMortgage REITs

Did Doubling Authorized Shares and a Steady Dividend Just Shift Dynex Capital's (DX) Investment Narrative?

Earlier in May 2026, Dynex Capital’s board declared a US$0.17 per-share cash dividend for May, payable on June 1, 2026, to shareholders of record as of May 21, 2026. At the same time, shareholders approved doubling the company’s authorized common shares to 720 million and backed board, compensation, and governance measures, signaling support for Dynex Capital’s evolving capital structure and leadership framework. We will now examine how the doubling of authorized common shares shapes Dynex...
NasdaqGS:AFRM
NasdaqGS:AFRMDiversified Financial

Assessing Affirm Holdings (AFRM) Valuation After New Google Pay And Gemini Integration

Affirm Holdings (AFRM) is back in focus after announcing that its buy now, pay later options will roll out across Google Search, AI Mode, and the Gemini app via Google Pay checkout. See our latest analysis for Affirm Holdings. The news around Google integration comes as Affirm's share price shows mixed momentum, with a 36.24% 90 day share price return and a 32.29% 1 year total shareholder return, but a year to date share price decline of 11.90% from the latest close of US$65.22. If this kind...
NYSE:FCN
NYSE:FCNProfessional Services

Does FTI Consulting’s (FCN) European Dealmaking Push Reveal a Deeper Shift in Its Advisory Focus?

Earlier in May 2026, FTI Consulting appointed Andreas P. Stöcklin to lead its Transactions practice across Continental Europe and named Emanuele Grasso as Senior Managing Director and head of the Corporate Finance segment in Italy, both joining the EMEA management structure to deepen M&A and transaction support capabilities. These hires bring decades of cross-border deal experience and board advisory expertise from firms such as Kroll and PwC, highlighting FTI Consulting’s intent to build...
NYSE:AU
NYSE:AUMetals and Mining

Should ABSA’s Downgrade And Insider Selling Shift How AngloGold Ashanti (AU) Investors View Management?

In recent months, AngloGold Ashanti has faced increased scrutiny as ABSA Securities downgraded the miner, while insiders, including the CEO and a director, sold shares without any offsetting insider purchases. This combination of analyst caution on costs and operations alongside ongoing insider selling raises fresh questions about how management views the company’s current positioning. Now we’ll examine how ABSA’s downgrade, rooted in mining cost inflation and operational risk, may reshape...
NYSE:SUI
NYSE:SUIResidential REITs

Assessing Sun Communities (SUI) Valuation As Shares Show Short-Term Momentum Shift

Sun Communities (SUI) has drawn investor attention after recent share moves, with the stock up 1.2% over the past day and 5.1% over the past week, despite declines over the past month. See our latest analysis for Sun Communities. The recent 7 day share price return of 5.1% contrasts with more muted year to date gains of 4.6% and a 1 year total shareholder return of 10.2%. This suggests near term momentum is improving from a softer medium term trend. If this move in Sun Communities has you...
NasdaqGS:ILMN
NasdaqGS:ILMNLife Sciences

How Adding Diagnostics Veteran David King To The Board At Illumina (ILMN) Has Changed Its Investment Story

Illumina, Inc. has added former Labcorp Executive Chairman and CEO David P. King to its Board of Directors, following the May 21, 2026 annual shareholder meeting and alongside equity grants to several directors as part of their compensation. King’s deep background in large-scale diagnostics businesses and clinical operations underlines Illumina’s push to embed genomics more firmly into everyday medical decision-making as it refreshes its Board. We’ll now examine how King’s board appointment,...
NasdaqGS:BMRN
NasdaqGS:BMRNBiotechs

Why BioMarin (BMRN) Is Up 8.9% After VOXZOGO’s Phase 3 Success In Hypochondroplasia Trial

Earlier in May 2026, BioMarin reported that its Phase 3 CANOPY-HCH-3 trial of VOXZOGO in children with hypochondroplasia met its primary endpoint, showing a statistically significant 2.33 cm/year gain in annualized growth velocity over placebo and meaningful improvements in arm span with a safety profile consistent with prior use in achondroplasia. Because hypochondroplasia currently has no approved therapies, these data and BioMarin’s plan to file a supplemental FDA application in the third...
NasdaqGS:BCPC
NasdaqGS:BCPCChemicals

Balchem (BCPC) Valuation Check After Mixed Momentum And Perceived 15.3% Undervaluation

How Balchem’s Recent Performance Frames the Story for Investors Balchem (BCPC) has been steady over the past day, but the stock is up about 1.4% over the past week and down roughly 7% over the past month, prompting closer investor attention. See our latest analysis for Balchem. That recent 7% one month share price pullback, alongside a 5.0% year to date share price gain and a 3 year total shareholder return of 34.3%, suggests momentum has cooled but long term holders have still been...
NYSE:OPY
NYSE:OPYCapital Markets

Assessing Oppenheimer Holdings (OPY) Valuation After Recent Share Price Pullback

Recent share performance and context Oppenheimer Holdings (OPY) has seen mixed share performance recently, with the stock down about 3% over the past day and roughly 9% over the past month, yet up around 9% in the past 3 months. See our latest analysis for Oppenheimer Holdings. Despite the recent 9% decline in the 1 month share price return to US$93.86, momentum over the year still looks constructive. A 29.21% year to date share price return and a 50.07% 1 year total shareholder return...
NasdaqGM:MVIS
NasdaqGM:MVISElectronic

Can MicroVision’s (MVIS) Narrowing Losses Quietly Reshape Its Lidar Commercialization Narrative?

In May 2026, MicroVision, Inc. reported first quarter 2026 results, with sales rising to US$935,000 from US$589,000 a year earlier, while net loss narrowed to US$25.29 million and basic loss per share improved to US$0.08 from US$0.12. This combination of higher sales and a smaller loss suggests incremental progress in MicroVision’s efforts to scale its lidar and perception technology business. We'll examine how this early revenue growth and reduced quarterly loss could influence...
NasdaqGS:MLCO
NasdaqGS:MLCOHospitality

Assessing Melco Resorts & Entertainment (NasdaqGS:MLCO) Valuation After Recent Share Price Weakness

Melco Resorts & Entertainment (MLCO) has been drawing attention after a period of weaker share performance, with the stock down over the past month and past 3 months. This has prompted closer scrutiny of its current valuation. See our latest analysis for Melco Resorts & Entertainment. At a latest share price of $5.38, Melco Resorts & Entertainment has seen its 7 day share price return fall 2.71% and its year to date share price return decline 28.36%, while the 5 year total shareholder return...
NYSE:POST
NYSE:POSTFood

A Look At Post Holdings (POST) Valuation After Recent Share Price Weakness

Why Post Holdings stock is on investors’ radar today Post Holdings (POST) is drawing attention after recent trading left the stock down over the past month and past 3 months, prompting investors to reassess its consumer packaged foods and foodservice footprint. At a recent close of US$97.17 and a market value of about US$4.4b, the company sits in the mid cap range for U.S. food and beverage stocks, with operations spanning cereals, pet food, refrigerated retail products, and foodservice...
NasdaqGM:MIRM
NasdaqGM:MIRMBiotechs

A Look At Mirum Pharmaceuticals (MIRM) Valuation After $600 Million Zero Coupon Convertible Note Offering

Mirum Pharmaceuticals (MIRM) has just completed a zero coupon convertible note offering of $600 million due 2032, a financing move that can reshape its capital structure and influence how investors assess the stock. See our latest analysis for Mirum Pharmaceuticals. Mirum’s recent zero coupon convertible note offering comes after a mixed stretch for the stock, with the share price up 26.32% year to date but down 8.24% over 90 days. The one year total shareholder return of 124.14% and five...
NYSE:BLDR
NYSE:BLDRBuilding

Does Builders FirstSource's (BLDR) ESOP Expansion and COO Succession Reveal a Deeper Cultural Strategy?

Builders FirstSource previously filed a US$41.62 million shelf registration for 6,050,000 common shares tied to its ESOP and confirmed a planned leadership transition naming Mike Hiller as Chief Operating Officer-designate while appointing Coley O’Brien as Chief Human Resources Officer. This combination of an employee-focused share offering and a long-term succession plan underscores the company’s emphasis on workforce alignment and operational continuity. We’ll now examine how the COO...
NasdaqGS:HUBG
NasdaqGS:HUBGLogistics

Hub Group (HUBG) Valuation Check After Nasdaq Non Compliance Notice And Reporting Delays

Hub Group (HUBG) recently received a Nasdaq notice of non compliance after missing the filing deadline for its March 31, 2026 Form 10 Q, highlighting ongoing restatements and extended reporting uncertainty. See our latest analysis for Hub Group. The Nasdaq notice comes after Hub Group signaled delayed filings earlier in May, yet the stock has held relatively firm, with a 1-day share price return of 1.92%, a 7-day share price return of 8.62%, and a 1-year total shareholder return of 26.17%...
NasdaqGS:OTEX
NasdaqGS:OTEXSoftware

Assessing Open Text (NasdaqGS:OTEX) Valuation After A Prolonged Share Price Pullback

Event overview and recent share performance Open Text (NasdaqGS:OTEX) has drawn fresh attention after a period in which the stock is down about 26% year to date and down about 38% over the past 3 years, prompting investors to reassess the business. See our latest analysis for Open Text. Recent price action has been choppy, with a 1 month share price return of 4.73%, a year to date share price return that is down 26.06%, and a 3 year total shareholder return that is down 37.97%, signaling that...
NasdaqGS:FLYW
NasdaqGS:FLYWDiversified Financial

How Driftwood’s Expanded Hotel Rollout At Flywire (FLYW) Has Changed Its Investment Story

Earlier this month, Driftwood Hospitality Management expanded its use of Flywire’s hospitality payments platform across nearly 90 U.S. hotel properties, digitizing contracts, deposits and multi-channel guest payments while cutting manual processing and fees, particularly through greater ACH adoption. This rollout shows how Flywire’s software-led payments model can reshape operational workflows for large hotel portfolios, pairing cost savings with a more seamless guest experience across major...
NasdaqGS:INBX
NasdaqGS:INBXBiotechs

How Positive INBRX-106 Phase 2 Data And Narrower Losses At Inhibrx Biosciences (INBX) Have Changed Its Investment Story

In May 2026, Inhibrx Biosciences reported a first-quarter net loss of US$33.44 million, narrower than a year earlier, and released positive interim Phase 2 data from its HexAgon trial of INBRX-106 plus pembrolizumab in first-line PD-L1 positive metastatic or unresectable recurrent head and neck squamous cell carcinoma. The interim data showed a higher confirmed objective response rate and the emergence of complete responses with the INBRX-106 combination, underscoring the potential...
NasdaqGS:SAIC
NasdaqGS:SAICProfessional Services

A Look At Science Applications International (SAIC) Valuation After Recent Share Price Momentum

Science Applications International (SAIC) has drawn fresh attention after its recent share performance, with the stock near US$100 and returns over the past 3 months outpacing its move over the past month. See our latest analysis for Science Applications International. At around US$100, the recent 3.99% 1 day and 14.19% 3 month share price returns suggest momentum has picked up again, even as the year to date share price return is slightly down and the 1 year total shareholder return has...
NasdaqGS:ONB
NasdaqGS:ONBBanks

A Look At Old National Bancorp (ONB) Valuation After Recent Share Price Move

Recent stock move puts Old National Bancorp in focus Old National Bancorp (ONB) is back on investors’ radar after a recent share price move, with the stock last closing at US$23.94 and posting mixed short term returns across the past week and month. See our latest analysis for Old National Bancorp. That recent share price move sits within a steady trend, with a 1-year total shareholder return of 19.13% and a 3-year total shareholder return above 2x, suggesting momentum has been building over...
NYSE:INVH
NYSE:INVHResidential REITs

Invitation Homes (INVH) Valuation Check As Shares Rebound Over The Short Term

What Invitation Homes Stock Investors Are Watching Now Invitation Homes (INVH) has drawn attention after recent trading, with the stock last closing at $29.29. Investors are weighing this price against the company’s cash flow profile and recent share performance. See our latest analysis for Invitation Homes. Recent trading has added to a steady short term upswing, with a 30 day share price return of 7.96% and a 90 day share price return of 14.10%. However, the 1 year total shareholder return...
NasdaqGS:META
NasdaqGS:METAInteractive Media and Services

Assessing Meta Platforms (META) Valuation After Recent Share Price Pullback

Meta Platforms stock performance snapshot Meta Platforms (META) has seen mixed share performance recently, with the stock up about 0.5% over the past day, slightly lower over the past week, and down over the past month and past 3 months. See our latest analysis for Meta Platforms. With the share price at US$610.26, Meta Platforms has recently pulled back, with the 30 day share price return down 9.6% and the year to date share price return down 6.2%. However, the 3 year total shareholder...
NasdaqGS:INSM
NasdaqGS:INSMBiotechs

Assessing Insmed (INSM) Valuation After Recent Share Price Weakness And Rare Disease Growth Hopes

Insmed (INSM) is back in focus after recent trading pulled the stock down about 21% over the past month and roughly 33% over the past 3 months, prompting fresh attention on its rare disease portfolio. See our latest analysis for Insmed. At a share price of US$106.24, Insmed has seen short term momentum fade, with the 30 day share price return down 21.4% and the year to date share price return down 40%, even though the 1 year total shareholder return is 57.3% and the 3 year total shareholder...
NYSE:CVS
NYSE:CVSHealthcare

Assessing CVS Health (CVS) Valuation As Investors Revisit The Stock’s Recent Performance

Why CVS Health is on investors’ radar now CVS Health (CVS) is drawing fresh attention after its stock moved around current levels near US$93, with returns over the past month and past 3 months contrasting with a weaker recent week. See our latest analysis for CVS Health. At a share price of US$93.26, CVS Health has seen its short term share price momentum cool in the past week, even after strong 1 month and year to date share price returns and solid multi year total shareholder returns. If...